{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:50:37Z","timestamp":1790790637647,"version":"4.1.0"},"reference-count":51,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["K12CA215110"],"award-info":[{"award-number":["K12CA215110"]}]},{"name":"NIH","award":["P50 CA121974"],"award-info":[{"award-number":["P50 CA121974"]}]},{"name":"NIH","award":["R01 CA216846"],"award-info":[{"award-number":["R01 CA216846"]}]},{"name":"NIH","award":["R01 CA227472"],"award-info":[{"award-number":["R01 CA227472"]}]},{"name":"NIH","award":["R01 CA266424"],"award-info":[{"award-number":["R01 CA266424"]}]},{"name":"NIH","award":["R01 CA269286"],"award-info":[{"award-number":["R01 CA269286"]}]},{"name":"NIH","award":["R01 CA269349"],"award-info":[{"award-number":["R01 CA269349"]}]},{"name":"NIH","award":["T32-CA233414-02"],"award-info":[{"award-number":["T32-CA233414-02"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The tumor microenvironment (TME) contributes to cancer progression and treatment response to therapy, including in renal cell carcinoma (RCC). Prior profiling studies, including single-cell transcriptomics, often involve limited sample sizes and lack spatial orientation. The TME of RCC brain metastases, a major cause of morbidity, also remains largely uncharacterized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed digital spatial profiling on the NanoString GeoMx platform using 52 validated immuno-oncology markers on RCC tissue microarrays representing progressive stages of RCC, including brain metastases. We profiled 76 primary tumors, 27 adjacent histologically normal kidney samples, and 86 metastases, including 24 brain metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed lower immune checkpoint (TIM-3 and CTLA-4), cytolytic (GZMA and GZMB), and T cell activation (CD25) protein expression in metastases compared with primary tumors in two separate cohorts. We also identified changes in macrophages in metastases, with brain metastases-susceptible patients showing less M1-like, inflammatory macrophage markers (HLA-DR and CD127) in metastatic samples. A comparison of brain metastases to extracranial metastases revealed higher expression of the anti-apoptotic, BCL-2-family protein BCL-XL and lower expression of the innate immune activator STING in brain metastases. Lower TIM-3 and CD40 in the TME of brain metastases appear to be associated with longer survival, a finding that requires further validation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared with primary tumors, RCC metastases, including brain metastases, express lower levels of numerous markers of immune activation and current or investigational therapeutic targets. Our findings may have important implications for designing future biomarker and treatment studies and may aid in development of brain metastases-specific therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007240","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:17:54Z","timestamp":1692191874000},"page":"e007240","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5202-3744","authenticated-orcid":false,"given":"David A","family":"Schoenfeld","sequence":"first","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-3187","authenticated-orcid":false,"given":"Myrto","family":"Moutafi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijana","family":"Djureinovic","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D","family":"Merkin","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebowale","family":"Adeniran","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"David A","family":"Braun","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Parisi","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David L","family":"Rimm","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Jilaveanu","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-9873","authenticated-orcid":false,"given":"Harriet M","family":"Kluger","sequence":"additional","affiliation":[{"name":"School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2025100305122114000_11.8.e007240.1","unstructured":"Society AC . Cancer Facts and Figures 2022. Atlanta: American Cancer Society, 2022."},{"key":"2025100305122114000_11.8.e007240.2","first-page":"454","article-title":"An Interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma","volume":"72","author":"Hasanov","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025100305122114000_11.8.e007240.3","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1016\/j.clgc.2019.01.017","article-title":"Immunotherapy is changing first-line treatment of metastatic renal-cell carcinoma","volume":"17","author":"Labriola","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2025100305122114000_11.8.e007240.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100305122114000_11.8.e007240.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025100305122114000_11.8.e007240.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"2025100305122114000_11.8.e007240.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2025100305122114000_11.8.e007240.8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus Cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with Immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025100305122114000_11.8.e007240.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with Nivolumab plus Ipilimumab versus Sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100305122114000_11.8.e007240.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp411"},{"key":"2025100305122114000_11.8.e007240.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25452"},{"key":"2025100305122114000_11.8.e007240.12","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of Cabozantinib for brain metastases in patients with renal cell carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100305122114000_11.8.e007240.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02218"},{"key":"2025100305122114000_11.8.e007240.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101"},{"key":"2025100305122114000_11.8.e007240.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y"},{"key":"2025100305122114000_11.8.e007240.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.016"},{"key":"2025100305122114000_11.8.e007240.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000319","article-title":"Characterization of tumor Mutation burden, PD-L1 and DNA repair genes to assess relationship to immune Checkpoint inhibitors response in metastatic renal cell carcinoma","volume":"8","author":"Labriola","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100305122114000_11.8.e007240.18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100305122114000_11.8.e007240.19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune Reprogramming during Immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100305122114000_11.8.e007240.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2016.12.001"},{"key":"2025100305122114000_11.8.e007240.21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-020-03619-0","article-title":"Melanoma brain metastases have lower T-cell content and Microvessel density compared to matched Extracranial metastases","volume":"152","author":"Weiss","year":"2021","journal-title":"J Neurooncol"},{"key":"2025100305122114000_11.8.e007240.22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.755"},{"key":"2025100305122114000_11.8.e007240.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100057","article-title":"Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases","volume":"6","author":"Steindl","year":"2021","journal-title":"ESMO Open"},{"key":"2025100305122114000_11.8.e007240.24","doi-asserted-by":"crossref","unstructured":"Zhang X , Yin X , Zhang H , et al . Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 2019;19. doi:10.1186\/s12885-019-5578-4","DOI":"10.1186\/s12885-019-5578-4"},{"key":"2025100305122114000_11.8.e007240.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113205"},{"key":"2025100305122114000_11.8.e007240.26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.urolonc.2017.05.006","article-title":"Heterogeneity in renal cell carcinoma","volume":"35","author":"Beksac","year":"2017","journal-title":"Urol Oncol"},{"key":"2025100305122114000_11.8.e007240.27","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8167"},{"key":"2025100305122114000_11.8.e007240.28","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6890-13-3","article-title":"Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors","volume":"13","author":"Aziz","year":"2013","journal-title":"BMC Clin Pathol"},{"key":"2025100305122114000_11.8.e007240.29","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/192406","article-title":"MET expression in primary and metastatic clear cell renal cell carcinoma: implications of correlative biomarker assessment to MET pathway inhibitors","volume":"2015","author":"Shuch","year":"2015","journal-title":"Biomed Res Int"},{"key":"2025100305122114000_11.8.e007240.30","doi-asserted-by":"crossref","first-page":"24990","DOI":"10.18632\/oncotarget.4572","article-title":"Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens","volume":"6","author":"Baine","year":"2015","journal-title":"Oncotarget"},{"key":"2025100305122114000_11.8.e007240.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2007.10.006"},{"key":"2025100305122114000_11.8.e007240.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0104"},{"key":"2025100305122114000_11.8.e007240.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0472-9"},{"key":"2025100305122114000_11.8.e007240.34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.990367","article-title":"Location matters: Lag3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have Prognostic importance","volume":"12","author":"Schoenfeld","year":"2022","journal-title":"Front Oncol"},{"key":"2025100305122114000_11.8.e007240.35","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2008.65"},{"key":"2025100305122114000_11.8.e007240.36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jtho.2022.04.009","article-title":"Discovery of biomarkers of resistance to immune Checkpoint blockade in NSCLC using high-Plex Digital spatial profiling","volume":"17","author":"Moutafi","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025100305122114000_11.8.e007240.37","unstructured":"Team RC . R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2022."},{"key":"2025100305122114000_11.8.e007240.38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150295"},{"key":"2025100305122114000_11.8.e007240.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7303"},{"key":"2025100305122114000_11.8.e007240.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0761"},{"key":"2025100305122114000_11.8.e007240.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9"},{"key":"2025100305122114000_11.8.e007240.42","doi-asserted-by":"crossref","unstructured":"Ali S , G\u00f3rska Z , Duchnowska R , et al . n.d. Molecular profiles of brain metastases: A focus on heterogeneity. Cancers;13:2645. doi:10.3390\/cancers13112645","DOI":"10.3390\/cancers13112645"},{"key":"2025100305122114000_11.8.e007240.43","doi-asserted-by":"crossref","unstructured":"Zhang X , Yin X , Zhang H , et al . Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 2019;19. doi:10.1186\/s12885-019-5273-5","DOI":"10.1186\/s12885-019-5273-5"},{"key":"2025100305122114000_11.8.e007240.44","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330"},{"key":"2025100305122114000_11.8.e007240.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2025100305122114000_11.8.e007240.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0861"},{"key":"2025100305122114000_11.8.e007240.47","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1158\/1078-0432.CCR-22-0669","article-title":"A Mesenchymal tumor cell state confers increased dependency on the BCL-XL Antiapoptotic protein in kidney cancer","volume":"28","author":"Grubb","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100305122114000_11.8.e007240.48","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4903-7"},{"key":"2025100305122114000_11.8.e007240.49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12032-017-0926-1","article-title":"PD-L2: A Prognostic marker in Chromophobe renal cell carcinoma","volume":"34","author":"Erlmeier","year":"2017","journal-title":"Med Oncol"},{"key":"2025100305122114000_11.8.e007240.50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1761"},{"key":"2025100305122114000_11.8.e007240.51","article-title":"Association of PD-L2 expression in human tumors with Atezolizumab activity","volume":"40","author":"Schulz","year":"2017","journal-title":"Oncol Res Treat"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:12:34Z","timestamp":1759493554000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jitc-2023-007240"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007240","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}